Hamid Nikbakht
Overview
Explore the profile of Hamid Nikbakht including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1876
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harutyunyan A, Chen H, Lu T, Horth C, Nikbakht H, Krug B, et al.
Cell Rep
. 2020 Nov;
33(7):108390.
PMID: 33207202
The discovery of H3K27M mutations in pediatric gliomas marked a new chapter in cancer epigenomics. Numerous studies have investigated the effect of this mutation on H3K27 trimethylation, but only recently...
2.
Nikbakht H, Jessa S, Sukhai M, Arseneault M, Zhang T, Letourneau L, et al.
Sci Rep
. 2020 Jan;
10(1):581.
PMID: 31953485
While comparison of primary tumor and metastases has highlighted genomic heterogeneity in colorectal cancer (CRC), previous studies have focused on a single metastatic site or limited genomic testing. Combining data...
3.
Weinberg D, Papillon-Cavanagh S, Chen H, Yue Y, Chen X, Rajagopalan K, et al.
Nature
. 2019 Sep;
573(7773):281-286.
PMID: 31485078
Enzymes that catalyse CpG methylation in DNA, including the DNA methyltransferases 1 (DNMT1), 3A (DNMT3A) and 3B (DNMT3B), are indispensable for mammalian tissue development and homeostasis. They are also implicated...
4.
Boileau M, Shirinian M, Gayden T, Harutyunyan A, Chen C, Mikael L, et al.
Nat Commun
. 2019 Jun;
10(1):2891.
PMID: 31253791
Our ability to manage acute myeloid leukemia (AML) is limited by our incomplete understanding of the epigenetic disruption central to leukemogenesis, including improper histone methylation. Here we examine 16 histone...
5.
Harutyunyan A, Krug B, Chen H, Papillon-Cavanagh S, Zeinieh M, De Jay N, et al.
Nat Commun
. 2019 Mar;
10(1):1262.
PMID: 30890717
Lys-27-Met mutations in histone 3 genes (H3K27M) characterize a subgroup of deadly gliomas and decrease genome-wide H3K27 trimethylation. Here we use primary H3K27M tumor lines and isogenic CRISPR-edited controls to...
6.
Gayden T, Sepulveda F, Khuong-Quang D, Pratt J, Valera E, Garrigue A, et al.
Nat Genet
. 2018 Nov;
51(1):196.
PMID: 30429576
In the version of this article originally published, the main-text sentence "In three patients of European ancestry, we identified the germline variant encoding p.Ile97Met in TIM-3, which was homozygous in...
7.
Gomes C, Gayden T, Bajic A, Harraz O, Pratt J, Nikbakht H, et al.
Nat Commun
. 2018 Nov;
9(1):4572.
PMID: 30385747
Giant cell lesions of the jaw (GCLJ) are debilitating tumors of unknown origin with limited available therapies. Here, we analyze 58 sporadic samples using next generation or targeted sequencing and...
8.
Gayden T, Sepulveda F, Khuong-Quang D, Pratt J, Valera E, Garrigue A, et al.
Nat Genet
. 2018 Oct;
50(12):1650-1657.
PMID: 30374066
Subcutaneous panniculitis-like T cell lymphoma (SPTCL), a non-Hodgkin lymphoma, can be associated with hemophagocytic lymphohistiocytosis (HLH), a life-threatening immune activation that adversely affects survival. T cell immunoglobulin mucin 3 (TIM-3)...
9.
Valera E, McConechy M, Gayden T, Rivera B, Jones D, Wittmann A, et al.
Acta Neuropathol
. 2018 Aug;
136(4):657-660.
PMID: 30143858
No abstract available.
10.
Salloum R, McConechy M, Mikael L, Fuller C, Drissi R, DeWire M, et al.
Acta Neuropathol Commun
. 2017 Nov;
5(1):78.
PMID: 29084603
Pediatric high-grade gliomas (pHGGs) are aggressive neoplasms representing approximately 20% of brain tumors in children. Current therapies offer limited disease control, and patients have a poor prognosis. Empiric use of...